Literature DB >> 8340530

Clinical criteria for differentiating between recessive and dominant forms of dystrophic epidermolysis bullosa, elaborated from an analysis of 119 cases.

K Nomura1, T Imaizumi, T Sato, I Hashimoto.   

Abstract

We attempted to establish clinical criteria which differentiated between recessive dystrophic epidermolysis bullosa (RDEB) and dominant DEB (DDEB), since these two groups show prominent differences in prognosis, genetic recurrence risk and response to some types of treatment. The total of 119 cases examined consisted of our own 9 cases (2 of RDEB and 7 of DDEB) and 110 cases (26 of RDEB and 84 of DDEB) collected from the medical literature. They were analyzed by calculating the sensitivity and specificity of ten clinical features. We concluded that, syndactyly, presence of complications, dental lesions, remission-less course, and oral lesions are strongly indicative of RDEB (more than 70% specific). Intractable skin ulcer is suggestive of RDEB (more than 55% specific). Nail lesions, scar and atrophy, milia and pigmentation are not helpful in the differentiation because of their commonality. The proposed criteria are simple, reliable, and practical, providing us with a useful tool for differentiation of RDEB and DDEB in daily practice.

Entities:  

Mesh:

Year:  1993        PMID: 8340530     DOI: 10.1111/j.1346-8138.1993.tb01390.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  Expression of collagenase and stromelysin in skin fibroblasts from recessive dystrophic epidermolysis bullosa.

Authors:  T Sato; K Nomura; I Hashimoto
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 2.  A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.

Authors:  Jean Yuh Tang; M Peter Marinkovich; Eleanor Lucas; Emily Gorell; Albert Chiou; Ying Lu; Jodie Gillon; Dipen Patel; Dan Rudin
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.